
Sign up to save your podcasts
Or


Thomas Philipson discusses a forthcoming study that calculates the immense economic value of eradicating cancer, estimating that eliminating the disease over a thirty-year period would be worth approximately $186 trillion to the American public. The conversation shifts from these staggering figures to the systemic barriers preventing such medical breakthroughs, specifically targeting the lengthy FDA approval process as a primary obstacle to innovation. Philipson argues that the government should focus strictly on regulating drug safety while allowing the private market and medical professionals to determine effectiveness through off-label use and real-world application.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By 77 WABC4.6
3434 ratings
Thomas Philipson discusses a forthcoming study that calculates the immense economic value of eradicating cancer, estimating that eliminating the disease over a thirty-year period would be worth approximately $186 trillion to the American public. The conversation shifts from these staggering figures to the systemic barriers preventing such medical breakthroughs, specifically targeting the lengthy FDA approval process as a primary obstacle to innovation. Philipson argues that the government should focus strictly on regulating drug safety while allowing the private market and medical professionals to determine effectiveness through off-label use and real-world application.
Learn more about your ad choices. Visit megaphone.fm/adchoices

23,355 Listeners

2,303 Listeners

12,947 Listeners

743 Listeners

5,660 Listeners

6,587 Listeners

43,939 Listeners

734 Listeners

6,294 Listeners

487 Listeners

599 Listeners

920 Listeners

215 Listeners

389 Listeners

1,180 Listeners